Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18083762 | 0.88 | RXFP1 (0.45) | RXFP1PTPN11ACKR3PTGESABCB1 | |
| SCHEMBL18083681 | 0.86 | ACKR3 (0.54) | RXFP1PTPN11ACKR3MAPTHIF1A | |
| SCHEMBL18083726 | 0.85 | GLS (0.45) | RXFP1PTPN11ACKR3MAPTPTGES | |
| SCHEMBL18083787 | 0.82 | CHRM3 (0.52) | ACKR3TRPV1KCNK3KCNK9HIF1A | |
| SCHEMBL18083781 | 0.79 | DGAT1 (0.53) | MAPTHIF1AEPAS1MEN1TSHR | |
| SCHEMBL20684900 | 0.76 | ACKR3 (0.56) | RXFP1PTPN11ACKR3MAPTHIF1A | |
| SCHEMBL18083728 | 0.75 | KCNK3 (0.53) | RXFP1KCNK3KCNK9ABL1SRC | |
| SCHEMBL18083772 | 0.74 | SMN1; SMN2 (0.64) | RXFP1PTPN11MAPTHIF1AEPAS1 | |
| SCHEMBL28864301 | 0.74 | ALDH1A1 (0.61) | MAPTMEN1TSHRKMT2A | |
| SCHEMBL20160543 | 0.74 | TP53 (0.48) | MAPTMEN1TSHRKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271348-B1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016146220-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| EP-3070084-A1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | FYN, LCK, LYN | RXFP1 1608/4885PTPN11 502/4885ACKR3 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.